State of the Art in Robotic Surgery with Hugo RAS System: Feasibility, Safety and Clinical Applications

Abstract

Since its introduction in the early 2000s, robotic surgery has represented a significative innovation within a minimally invasive surgery approach. A variety of robotic platforms have been made available throughout the years, and the outcomes related to those platforms have been described in the literature for many types of surgeries. Medtronic’s HugoTM RAS system is one of the newest robotic generations launched, but because of its recent placing on the field, comprehensive clinical data are still lacking. The aim of the present state of the art is to address the current literature concerning the use of the HugoTM RAS robot in order to report its feasibility, safety and clinical applications in different surgical branches. Two reviewers independently conducted a search on the “PubMed” electronic database, using the keywords “Hugo” and “Hugo RAS”. After the initial screening of 35 results, a total of 15 articles concerning the Hugo RAS system were selected for the review, including both oncological and benign surgery. Patients’ demographic and baseline data were compared including, when available, docking system times, complications and oncological outcomes in the fields of urologic, gynecologic and general surgery. With reference to urological procedures, a total of 156 robot-assisted radical prostatectomies, 10 robot-assisted partial nephrectomies, and 5 robot-assisted adrenalectomies were performed, involving a total of 171 patients. The surgical branch in which the Hugo system found its major application was urology, which was followed by gynecology and general surgery. The Hugo RAS system by Medtronic represents an innovative and safe surgical platform, with excellent perspective for the future and different clinical applications in many surgical branches. More studies are needed to validate the safety and results from this new robotic platform.

Robot-assisted partial nephrectomy using the novel Hugo™ RAS system: Feasibility, setting and perioperative outcomes of the first off-clamp series

“…The Hugo™ RAS system currently stands as the most broad alternative to the well-known Da Vinci system, showing greater potential for application in the realm of minimally-invasive urology. [13][14][15][16][17][18] Drawing on existing literature, the Hugo™ RAS system appears to be deployable safely and effectively in various urological procedures. While this modern technology has added value to the range of minimally invasive urological surgical options, further research with a larger patient cohort is needed to refine operative techniques and comprehend the perioperative outcomes of Hugo™ RAS, especially when compared to other robotic surgical platforms.…”

“…Medtronic's Hugo™ RAS system embodies a cutting-edge and secure surgical platform, with promising prospects for the future. 18 In the context of kidney tumors, an expanding number of larger and more intricate kidney lesions are being addressed through minimally invasive means. Robotassisted partial nephrectomy (RAPN) stands as an everevolving and refined essential urological procedure.…”

Trifecta Outcomes of Robot-Assisted Partial Nephrectomy Using the New Hugo™ RAS System Versus Laparoscopic Partial Nephrectomy

“…In this scenario, since DaVinci platform patent has expired breaking the robotic market monopoly, more robotic systems have emerged offering surgeons supplementary surgical opportunities [18]. The Hugo™ RAS System by Medtronic is one of the most recent platforms, demonstrating interesting results across several procedures, such as RAPN [19]. Nevertheless, consistent and reproducible data regarding NSS are still lacking.…”

Preclinical Setup Standardization of the Novel HugoTM Robotic Platform for Upper Gastrointestinal Surgery

“…This demonstrates that Hugo™ is safe and effective in performing UGI surgery.The data obtained from this preclinical study has allowed to standardize the approach to the abdominal upper quadrants with Hugo™. Although it's a preclinical work, the initial clinical experiences that have been published so far are con rming our results.Hugo™ RAS have already used our suggested setup [14][15][16][17] , we advocate that our standardization would be adopted in a more widespread fashion, to improve e ciency and reproducibility.…”

“…Hugo™ RAS have already used our suggested setup [14][15][16][17] , we advocate that our standardization would be adopted in a more widespread fashion, to improve e ciency and reproducibility.…”